"Nephros is pleased to have received approval from the Therapeutic Products Directorate to market its Dual Stage Ultrafilters in Canada," said Dr. Paul Mieyal, Acting CEO of Nephros, Inc. "Recent data have shown that the Nephros DSU, when used as part of the water purification system for dialysis systems, may reduce the required dosage of erythropoietin stimulating agents, which we believe will provide a unique benefit to patients. We are proud to have the opportunity to introduce this important product to dialysis patients in Canada."
According to the Canadian Organ Replacement Registry (CORR), in 2009 there were approximately 38,000 patients with End-Stage Renal Disease in Canada.
